Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.

A few companies are in clinicals with novel approaches to heal an initial brain injury or minimize secondary damage. Slow progress may be more related to investors’ misperceptions of the topic than ...

Cell-engineering company, MaxCyte, Inc., announced it will acquire SeQure Dx, which focuses on editing assessment services for cell and gene therapies, for $4.5 million. The all-cash deal includes ...

Obstructive uropathy secondary to malignant ureteral strictures is rare, with carcinoma of the breast accounting for less than 2% of cases. We present the case of a woman in her late 50s with a ...

A retrospective analysis was performed on PDAC patients with R0 resection from April 2008 to July 2017 in Fudan University Shanghai Cancer Center (FUSCC ... Further studies and additional clinical ...

Video Back Videos home Signature collection Essentials collection Artificial Intelligence ...

Methods Systematic review and meta-analysis to identify randomised controlled trials of cannabinoids compared with placebo/other active agents for the treatment of cancer-related pain ... are shown in ...

Figure 1 Consort Flow-diagram. Microsoft Excel and GraphPad ... Immune-checkpoint inhibitors (ICI) are one of the most important clinical advances for a wide range of malignancies, including melanoma ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

Cancer researcher Karen Sfanos says she is 'terrified' of the impact of cuts to NIH funding that supports vital biomedical ...

In a survey, less than half of cancer patients and their family members said they were willing to participate in a clinical trial, and about a third of respondents said they had a positive perception ...